RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

References

• Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5(4):1–9. doi:10.1007/s40121-016-0130-1.
   PubMedGoogle Scholar
• Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127–132. doi:10.1067/S0022-3476(03)00510-9.
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/S0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets. 2012;12(2):92–97. doi:10.2174/187152612800100099.
   PubMedGoogle Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98. doi:10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Kong AM, Winer IH, Zimmerman NM, Diakun D, Bloomfield A, Gonzales T, Fergie J, Goldstein M, Krilov LR. Increasing rates of RSV hospitalization among preterm Infants: a decade of data. Am J Perinatol. 2021. doi:10.1055/s-0041-1736581.
   Google Scholar
• García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A. Risk factors in children hospitalized with RSV bronchiolitis versus non–RSV bronchiolitis. Pediatrics. 2010;126(6):e14530e11460. doi:10.1542/peds.2010-0507.
   Web of Science ®Google Scholar
• Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(5 Suppl):S112–117. doi:10.1067/S0022-3476(03)00508-0.
   PubMed Web of Science ®Google Scholar
• Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. 2021;148(3). doi:10.1542/peds.2021-052089.
   PubMed Web of Science ®Google Scholar
• Sucasas Alonso A, Pertega Diaz S, Saez Soto R, Avila-Alvarez A. Epidemiology and risk factors for bronchopulmonary dysplasia in premature infants born at or less than 32 weeks of gestation. An Pediatr (Engl Ed). 2021. doi:10.1016/j.anpedi.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Bell EF, Hintz SR, Hansen NI, Bann CM, Wyckoff MH, DeMauro SB, Walsh MC, Vohr BR, Stoll BJ, Carlo WA, et al. Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013-2018. JAMA. 2022;327(3):248–63. doi:10.1001/jama.2021.23580.
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, Laptook AR, Sánchez PJ, Van Meurs KP, Wyckoff M, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314(10):1039–51. doi:10.1001/jama.2015.10244.
   PubMed Web of Science ®Google Scholar
• Taylor GL, O’Shea TM. Extreme prematurity: risk and resiliency. Curr Probl Pediatr Adolesc Health Care. 2022;52(2):101132. doi:10.1016/j.cppeds.2022.101132.
   PubMed Web of Science ®Google Scholar
• Haerskjold A, Kristensen K, Kamper-Jorgensen M, Nybo Andersen AM, Ravn H, Graff Stensballe L. Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children. Pediatr Infect Dis J. 2016;35(1):61–65. doi:10.1097/INF.0000000000000924.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90(1):F64–68. doi:10.1136/adc.2003.029710.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620–638. doi:10.1542/peds.2014-1666.
   PubMedGoogle Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–37. doi:10.1542/peds.102.3.531.
   Web of Science ®Google Scholar
• Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;30(4). doi:10.1002/14651858.CD006602.pub4.
   Google Scholar
• Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American academy of pediatrics committee on infectious diseases and committee of fetus and newborn. Pediatrics. 1998;102(5):1211–16. doi:10.1542/peds.102.5.1211.
   PubMedGoogle Scholar
• Meissner HC, Long SS, American academy of pediatrics committee on infectious D, committee on F, Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 Pt 1):1447–52. doi:10.1542/peds.112.6.1447.
   PubMed Web of Science ®Google Scholar
• Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade S, Pavilack M, McLaurin K. The 2014–2015 national impact of the 2014 American academy of pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol. 2018;35(2):192–200. doi:10.1055/s-0037-1606352.
   PubMed Web of Science ®Google Scholar
• Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017. Hum Vaccin Immunother. 2021;17(5):1536–45. doi:10.1080/21645515.2020.1822134.
   PubMed Web of Science ®Google Scholar
• Goldstein M, Krilov LR, Fergie J, Brannman L, Wade SW, Kong AM, Ambrose CS. Unintended consequences following the 2014 American academy of pediatrics policy change for palivizumab prophylaxis among infants born at less than 29 weeks’ gestation. Am J Perinatol. 2021;38(S 01):e201–06. doi:10.1055/s-0040-1709127.
   PubMedGoogle Scholar
• Goldstein M, Krilov LR, Fergie J, McLaurin K, Wade S, Diakun D, Lenhart G, Bloomfield A, Kong A. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016. Am J Perinatol. 2018;35(14):1433–42. doi:10.1055/s-0038-1660466.
   PubMed Web of Science ®Google Scholar
• Fergie J, Suh M, Jiang X, Fryzek JP, Gonzales T. Respiratory syncytial virus and all-cause bronchiolitis hospitalizations among preterm infants using the pediatric health information system (PHIS). J Infect Dis. 2022;225(7):1197–204. doi:10.1093/infdis/jiaa435.
   PubMed Web of Science ®Google Scholar
• Rajah B, Sanchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr. 2017;181:183–8 e181. doi:10.1016/j.jpeds.2016.10.074.
   PubMed Web of Science ®Google Scholar
• Gross I, Siedner-Weintraub Y, Abu Ahmad W, Bar-Oz B, Eventov-Friedman S. National evidence in Israel supporting reevaluation of respiratory syncytial virus prophylactic guidelines. Neonatology. 2017;111(3):240–46. doi:10.1159/000452196.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–348. doi:10.1542/peds.2013-0303.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants. Am J Perinatol. 2020;37(2):174–83. doi:10.1055/s-0039-1694008.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Forbes ML, Goldstein M, Wadhawan R, Stewart DL. Severity and cost of RSV hospitalization among US preterm infants following the 2014 American Academy of pediatrics policy change. Infect Dis Ther. 2021;10(Suppl 1):27–34. doi:10.1007/s40121-020-00389-0.
   PubMed Web of Science ®Google Scholar
• Ricco M, Ferraro P, Peruzzi S, Zaniboni A, Ranzieri S. Respiratory syncytial virus: knowledge, attitudes and beliefs of general practitioners from North-Eastern Italy (2021). Pediatr Rep. 2022;14(2):147–65. doi:10.3390/pediatric14020021.
   PubMed Web of Science ®Google Scholar
• Weiner JH. Respiratory syncytial virus infection and palivizumab: are families receiving accurate information? Am J Perinatol. 2010;27(3):219–23. doi:10.1055/s-0029-1239493.
   PubMed Web of Science ®Google Scholar